773 related articles for article (PubMed ID: 23241745)
1. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
2. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
5. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
Reichling LJ; Riddle SM
Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 dephosphorylation increases its ubiquitination.
Zhao J; Molitor TP; Langston JW; Nichols RJ
Biochem J; 2015 Jul; 469(1):107-20. PubMed ID: 25939886
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
Kamikawaji S; Ito G; Sano T; Iwatsubo T
Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
[TBL] [Abstract][Full Text] [Related]
11. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
12. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Rudenko IN; Chia R; Cookson MR
BMC Med; 2012 Feb; 10():20. PubMed ID: 22361010
[TBL] [Abstract][Full Text] [Related]
13. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
15. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
[TBL] [Abstract][Full Text] [Related]
17. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
18. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.
Carballo-Carbajal I; Weber-Endress S; Rovelli G; Chan D; Wolozin B; Klein CL; Patenge N; Gasser T; Kahle PJ
Cell Signal; 2010 May; 22(5):821-7. PubMed ID: 20074637
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
20. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
